Ongoing research indicates that targeting the regulatory elements of the TP53 pathway, particularly using MDM2 inhibitors, offers a promising strategy for enhancing treatment outcomes in NB characterized by impaired TP53 signaling [13,37,39]. This evidence concerns the gene TP53 and neuroblastoma.